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Abstract
Objective To investigate whether an adjuvanted pandemic A/H1N1
2009 influenza vaccine in pregnancy was associated with an increased
risk of fetal death.
Design Nationwide register based cohort study.
Setting Denmark.
Participants All clinically recognised singleton pregnancies that ended
between November 2009 and September 2010. Individual level data on
exposure to an inactivated AS03 pandemic A/H1N1 2009 influenza
vaccine (Pandemrix) and potential confounders were linked to the study
cohort using a unique person identifier.
Main outcome measures The primary outcome measure was risk of
fetal death (spontaneous abortion and stillbirth combined) in H1N1
vaccinated compared with unvaccinated pregnancies, adjusting for
propensity scores. Secondary outcome measures were spontaneous
abortion (between seven and 22 weeks’ gestation) and stillbirth (after
22 completed weeks’ gestation).
Results The cohort comprised 54 585 pregnancies; 7062 (12.9%) women
were vaccinated against pandemic A/H1N1 2009 influenza during
pregnancy. Overall, 1818 fetal deaths occurred (1678 spontaneous
abortions and 140 stillbirths). Exposure to the H1N1 vaccine was not
associated with an increased risk of fetal death (adjusted hazard ratio
0.79, 95% confidence interval 0.53 to 1.16), or the secondary outcomes
of spontaneous abortion (1.11, 0.71 to 1.73) and stillbirth (0.44, 0.20 to
0.94). Estimates for fetal death were similar in pregnant women with
(0.82, 0.44 to 1.53) and without comorbidities (0.77, 0.47 to 1.25).
Conclusion This large cohort study found no evidence of an increased
risk of fetal death associated with exposure to an adjuvanted pandemic
A/H1N1 2009 influenza vaccine during pregnancy.
Introduction
Pregnant women are at higher risk of morbidity from seasonal
influenza infection, and studies from previous pandemics have
found that influenza infection in pregnancy is associated with
increased mortality.
1-4 Early in the outbreak of pandemic
A/H1N1 2009 influenza reports suggested a high risk of
morbidityandmortalityassociatedwithinfectioninpregnancy.
5
Consequently, pregnant women were included among the
prioritisedtargetgroupsinthethenupcomingH1N1vaccination
campaigns, and at least 322 000 pregnant women were
vaccinated in Europe alone.
6 7
Available evidence on the risks to the fetus of influenza
vaccination in pregnancy is, however, limited to only a handful
of studies of mainly inactivated seasonal influenza vaccines.
3 8
The few studies dealing with fetal risks associated with
pandemic A/H1N1 2009 influenza vaccine in pregnancy have
relied on passive pharmacovigilance surveillance or designs
withoutcontrolgroups.
7 9-14Althoughthedatahavenotindicated
an increased risk, the designs of these studies have precluded
an adequate analytical approach and they have therefore not
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Research
RESEARCHbeen able to exclude risks to the fetus. Thus, comparative
analytical studies are needed to accurately assess the safety of
H1N1 vaccines.
We carried out a nationwide register based cohort study to
investigate whether there was an increased risk of fetal death
(spontaneous abortion and stillbirth) after vaccination with an
AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine
among pregnant women in Denmark.
Methods
We constructed a cohort comprising all singleton pregnancies
(live births, stillbirths, and pregnancies with an abortive
outcome) in Denmark that ended between 2 November 2009
and 30 September 2010. Among women with several
pregnanciesinthisperiod,weincludedonlythefirst.Welinked
information on H1N1 vaccination and potential confounders to
the pregnant women in the cohort using their unique personal
identification numbers.
15 The primary outcome was fetal death
(spontaneous abortion and stillbirth combined). The secondary
outcomes were spontaneous abortion (defined as occurring
betweenthestartofweek7andtheendofweek22ofgestation)
and stillbirth (defined as delivery of a dead fetus after 22
completed weeks of gestation
16) analysed separately.
We obtained information on live births and stillbirths from the
medical birth register,
17 which contains detailed records on all
birthsinDenmark,includingthepersonalidentificationnumber
of the parents and the newborn, date of birth, and gestational
age. The national patient register contains individual level data
on all inpatients and outpatients in Danish hospitals, including
personal identification number, dates of contact or admission
and discharge, and diagnoses, classified according to the
international classification of diseases (10th revision).
18 From
this register we obtained information on pregnancies with an
abortive outcome: spontaneous abortion (ICD-10 codes O021,
O03),ectopicpregnancy(O00),hydatidiformmole(O01),other
abnormal products of conception (O020, O028-029), and
induced abortion (O04-08). The positive predictive value of a
registered diagnosis of spontaneous abortion was 99% when
confirmed by review of the medical records.
19 For pregnancies
with an abortive outcome, gestational age is indicated by a
supplementary code.
The onset of pregnancy was defined as the first day of the last
menstrualperiodandwasestimatedbysubtractionofgestational
age from the date of birth or the date of abortive outcome.
Recording of gestational age is based on the women’s report of
the first day of their last menstrual period; the date of the first
day of the last menstrual period is usually corrected according
to ultrasonography measurements.
20
We excluded women with a missing or implausible gestational
age, an abortive outcome at a gestational age of less than six
completed weeks, a diagnosis of an abortive outcome within
six weeks before the index pregnancy for pregnancies with an
abortive outcome (to avoid double register entries), pregnancy
onsetbefore1February2009orafter6December2009(unlikely
tobevaccinated),andthosewhohadreceivedH1N1vaccination
preceding the onset of pregnancy.
Pandemic A/H1N1 2009 influenza vaccine
TheDanishH1N1vaccinationprogrammetargetedpeoplewith
chronic diseases, key government staff, healthcare staff, and
pregnantwomen.
21-23Vaccinationwasrecommendedatanytime
in pregnancy, including the first trimester after individual
assessment, to pregnant women with chronic diseases;
vaccinationwasrecommendedinthesecondandthirdtrimesters
to pregnant women without comorbidities.
21 The vaccination
campaign started on 2 November 2009, and the only vaccine
used in Denmark was the monovalent inactivated AS03
adjuvanted split virion H1N1 vaccine (Pandemrix,
GlaxoSmithKline Biologicals, Rixensart, Belgium). Pandemic
vaccination was provided mainly by general practitioners and
also by hospitals and private clinics. We obtained information
on vaccination status from a national H1N1 vaccination
database, set up at Statens Serum Institut with the aim of
nationwidesurveillanceofvaccinationcoverage,effectiveness,
and safety. During the pandemic, all vaccine providers were
mandated, by law, to report and register the personal
identification number of the vaccinee and the date of
vaccination.Additionally,reportingwasobligatorytoreimburse
costsfromthenationalhealthinsurance.Thereforethedatabase
is considered close to complete.
Potential confounders
Weincludedthefollowingvariablesinapropensityscoremodel:
maternal age, county of residence, degree of urbanisation at
place of residence, and country of birth (central person
register
15); parity (medical birth register), history of fetal death
in siblings (medical birth register and national patient register),
selected comorbidities (see supplementary table 1) and number
of hospital admissions and outpatient hospital contacts within
three years preceding pregnancy (national patient register), and
selecteddrugs(seesupplementarytable1)andnumberofdrugs
usedwithinsixmonthsbeforepregnancy(nationalprescription
register
24). The prescription register contains individual level
informationonallprescriptionsfilledatallDanishpharmacies,
including personal identification number, date of filling the
prescription, and the Anatomic Therapeutic Chemical code.
Using logistic regression (SAS procedure LOGISTIC; SAS
statisticalsoftwareversion9.2),weestimatedapropensityscore
for each woman as the predicted probability of vaccination
conditional on all given covariates. Additionally, we included
in the propensity score all two way interactions between
covariates, except for comorbidities and drugs. We used mode
imputation for variables with missing values. Three different
propensity scores were estimated, one for each analysis: fetal
death (exposure between pregnancy onset and birth),
spontaneous abortion (exposure between pregnancy onset and
week22),andstillbirth(exposurebetweenpregnancyonsetand
birth).Aftercalculatingpropensityscores,weexcludedwomen
withanon-overlappingprobabilityofvaccineexposuretolimit
unmeasured confounding from those at the extreme ends of the
propensity score distribution.
25
Statistical analysis
Pregnancies started contributing person time to the cohort on 2
November 2009 or the start of week 7 of gestation, whichever
occurred latest, and were followed to fetal death or live birth.
Wecensoredpregnanciesendingwithanabortiveoutcomeother
than spontaneous abortion. In the subanalysis of spontaneous
abortion, we excluded pregnancies without follow-up in weeks
7-22 of gestation. In the subanalysis of stillbirth, we excluded
pregnancies without follow-up after 22 completed weeks of
gestation.
We used the Kaplan-Meier method to generate survival curves
according to vaccination status. Cox proportional hazards
regression with gestational age in days as the underlying time
scale was used to estimate hazard ratios with 95% confidence
intervals,comparingthehazardratesoffetaldeathamongH1N1
vaccinated and unvaccinated women (SAS procedure
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2794 doi: 10.1136/bmj.e2794 (Published 2 May 2012) Page 2 of 13
RESEARCHPHREG).
26 27 To assess the validity of the proportional hazards
assumption, we performed a Wald test for the interaction
between each independent variable and gestational age. If the
assessmentindicatednon-constanteffectovertime,weincluded
an interaction term in the model. Vaccination was treated as a
time dependent variable, thus reflecting vaccination status at a
given point in time during pregnancy. Possible confounders
wereincludedinthemodelsthroughpropensityscores,classified
into distribution fifths.
Common contraindications to vaccination (for example, acute
(febrile) illness) may also be associated with an increased risk
offetaldeath;thiswouldbiasresultstowardsaprotectiveeffect
of vaccination, at least in the period immediately after
vaccination.Inallanalyseswethereforeestimatedhazardratios
allowing for a two week period immediately after vaccination;
this two week period was removed from the main analysis and
analysed separately.
In sensitivity analyses, we estimated hazard ratios in women
with and without comorbidities by trimester of vaccination
without removing the two week period after vaccination from
the main analysis, and allowing for a six week period after
vaccination (removed from the main analysis). We also
estimated the risk of stillbirth, including smoking status and
prepregnancy body mass index, in the propensity score (these
data, from the medical birth register, were available only for
stillbornandliveborninfants).Additionally,weadjustedmodels
for influenza infection as a time varying variable. Influenza
infectionwasdefinedasahospitaloutpatientcontactorinpatient
admission for influenza (ICD-10 code J09-11), or a filled
prescription for an anti-influenza antiviral (Anatomic
Therapeutic Chemical code J05AH01-02). Furthermore, we
used the array approach sensitivity analysis described by
Schneeweisstoestimatetheeffectofanunmeasuredconfounder
on the observed estimates.
28
Results
Fetal death
A total of 75 483 pregnancies ended during 2 November 2009
and 30 September 2010, of which 20 848 were excluded (fig
1⇓). The C statistic for the propensity score for exposure to
vaccine between pregnancy onset and birth was 0.62. After
exclusion of 50 pregnancies with non-overlapping propensity
scores, the final study cohort for the outcome of fetal death
comprised54585pregnancies;theseendedin50552livebirths
(92.6%), 1678 spontaneous abortions (3.1%), 140 stillbirths
(0.3%), and 2215 other abortive pregnancy outcomes (4.1%).
A total of 7062 (12.9%) women were vaccinated against H1N1
influenzaduringpregnancy,withmostcohortparticipantsbeing
vaccinatedinthesecondhalfofNovember(fig2⇓).Vaccinated
women had higher parity, were slightly older, were slightly
morelikelytohavebeenborninDenmark,andweremorelikely
to live in the capital, to have had a previous pregnancy ending
infetaldeath,tohaveselectedcomorbiditiessuchaspulmonary
disease and diabetes, to have been admitted to hospital in the
past three years, to have had an outpatient hospital contact in
the past three years, and to have used drugs in the past six
months (table 1⇓). A large proportion of women had no
registered comorbidities (table 1).
The unadjusted survival curves between vaccinated and
unvaccinated women were similar (fig 3⇓). The risk of fetal
death associated with H1N1 vaccination in pregnancy was not
increased in either unadjusted (hazard ratio 0.82, 95%
confidence interval 0.55 to 1.20) or adjusted analyses (0.79,
0.53 to 1.16; table 2⇓). There was a non-significant decreased
risk of fetal death in the two week period immediately after
vaccination(sixexposedcases;adjustedhazardratio0.48,95%
confidence interval 0.22 to 1.10).
Spontaneous abortion
From the principal cohort an additional 19 088 pregnancies
without follow-up between week 7 and 22 of gestation and 139
pregnancies with non-overlapping propensity scores were
excluded (fig 1). The C statistic for the propensity score for
exposuretovaccinebetweenpregnancyonsetandweek22was
0.65. Among the 35 408 (2736 (7.7%) vaccinated) contributing
pregnancies in this cohort, followed between week 7 and 22 of
gestation, 1674 (4.7%) spontaneous abortions occurred. (See
supplementary table 2 for the characteristics of participants in
this cohort.) No increased risk of spontaneous abortion was
observed after H1N1 vaccination in either unadjusted (hazard
ratio 1.16, 95% confidence interval 0.74 to 1.80) or adjusted
analyses (1.11, 0.71 to 1.73). There was a non-significant
decreased risk of spontaneous abortion in the two week period
immediately after vaccination (five exposed cases; adjusted
hazard ratio 0.47, 95% confidence interval 0.19 to 1.13).
Stillbirth
From the principal cohort, 3905 pregnancies with no follow-up
after 22 completed weeks of gestation and 53 pregnancies with
non-overlapping propensity scores were excluded (fig 1). The
Cstatisticforpropensityscoreforexposuretovaccinebetween
week 23 and birth was 0.63. Among the 50 677 (7014 (13.8%)
vaccinated)contributingpregnanciesinthiscohort,139(0.3%)
stillbirths were observed. (See supplementary table 3 for the
characteristicsofparticipantsinthiscohort.)Theriskofstillbirth
after H1N1 vaccination decreased in both unadjusted (hazard
ratio 0.43, 95% confidence interval 0.20 to 0.92) and adjusted
analyses(0.44,0.20to0.94;table2).Therewasnosignificantly
decreased risk of stillbirth in the two week period after
vaccination (one exposed case; adjusted hazard ratio 0.58, 95%
confidence interval 0.08 to 4.18).
Sensitivity analyses
The risk of fetal death was estimated in pregnant women with
and without any registered predefined comorbidities: hazard
ratios were similar in these two groups (table 3⇓). In analyses
of fetal death according to trimester of vaccination, the risk
associated with vaccination in the first trimester was not
significantly increased (table 3); there was a significantly
decreased risk associated with vaccination in the second
trimester and no significantly increased risk associated with
vaccination in the third (table 3). In analyses of all three
outcomes without removing the two week period after
vaccination and also when increasing the duration of the period
to six weeks, the hazard ratios tended towards zero (table 3).
For the analysis of stillbirth, the estimate was not changed by
includingsmokingandbodymassindexinthepropensityscore
(table 3). When influenza infection was included as a time
varyingcovariateinthemodels,thehazardratiodidnotchange
for any of the three outcomes (table 3). Finally, the potential
effect of an unmeasured confounder was modelled on the fetal
death outcome. A confounder that would mask a true risk
associated with vaccination would be of primary concern; it
was therefore assumed that those receiving vaccination had a
lower prevalence of an unmeasured confounder that was
associatedwithincreasedriskoffetaldeath(seesupplementary
table 4). For example, if 20% of the non-vaccinated and 10%
of the vaccinated women had the confounder, and the
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RESEARCHconfounder increased the relative risk of fetal death by 3, the
observed estimate of 0.8 would be biased by 14% and a
confounderadjustedestimatewouldbe0.9.Assumingagreater
difference in prevalence of confounders between groups, 20%
in the non-vaccinated and 0% in the vaccinated, and a
confounder associated relative risk of 3, the observed estimate
of 0.8 would be biased by 29% and a confounder adjusted
estimatewouldbe1.1.Assumingalargerconfounderassociated
relative risk of 5.5 with prevalence of confounders of 20% and
10%, the observed estimate of 0.8 would be biased by 24% and
a confounder adjusted estimate would be 1.0. A similar but
alternative scenario was also modelled, assuming a higher
prevalence of a protective unmeasured confounder among the
vaccinated women (see supplementary table 5). For example,
if50%ofthevaccinatedwomenand20%ofthenon-vaccinated
women had a confounder with a relative risk for fetal death of
0.4, the observed estimate of 0.8 would be biased by 20% and
a confounder adjusted estimate would be 1.0.
Discussion
Inthislargenationwidecohortstudy,vaccinationwithanAS03
adjuvanted pandemic A/H1N1 2009 influenza vaccine in
pregnancy was not associated with an increased risk of the
primary composite outcome of fetal death, or its components
spontaneousabortionandstillbirth.Giventheupperlimitofthe
confidence interval, these data allowed the exclusion of a 17%
increasedriskoffetaldeath,a74%increasedriskofspontaneous
abortion, and any risk of stillbirth associated with vaccination.
Resultsweresimilarinhealthypregnantwomenandthosewith
comorbidities.
Comparison with other studies
Previous reports on the fetal safety of H1N1 vaccination,
although reassuring, have been non-analytical and limited in
size. The Vaccine Adverse Events Reporting System in the
UnitedStatesreceived131reportsofpregnancyspecificevents
in women receiving non-adjuvanted H1N1 vaccines, with
spontaneous abortion (n=95) and stillbirth (n=18) representing
the most common events
11; estimated reporting rates were
considerablylowerthanexpectedrates.Areviewofspontaneous
reports received by the European Medicines Agency identified
130pregnancyrelatedoutcomes,including57abortionsand49
intrauterinedeathsorstillbirths.Giventhenumberofvaccinated
women and background rates, this, in addition to data provided
by the manufacturers, was not considered to indicate increased
risk.
7 14 Similarly, pharmacovigilance reports from Taiwan and
France found a lower than expected number of reported
events.
10 13 These studies, based on data from passive
surveillance systems, have limitations; importantly, although
they can generate risk signals, they cannot exclude risks. Two
descriptive cohort studies have been published. In a
post-authorisationstudyoftheAS03adjuvantedH1N1vaccine
in the United Kingdom, pregnancy outcomes from 265
vaccinated pregnant women were reported
12; the prevalence of
spontaneous abortions and stillbirths was comparable to
expected rates. A French study had outcome data for 569
pregnant women receiving a non-adjuvanted H1N1 vaccine;
rates of fetal death (unclear definition) and stillbirth were not
higher than in other surveys.
9 Thus our cohort study confirms
thefindingsfromlimitedpreviousreportsandexpandsonthese
findings by providing the first detailed comparative analysis of
the risk of fetal death associated with H1N1 vaccination.
Pandemrix is a split virion vaccine produced from the
A/California/7/2009(H1N1)v-likestrainandcontainsanAS03
adjuvant (composed of squalene, DL-α-tocopherol, and
polysorbate 80). Our results are principally applicable to this
particular vaccine. Additionally, we believe that results are
generalisable to non-adjuvanted vaccines produced from this
virus strain (although these generally have a higher content of
the antigen haemagglutinin) but not to vaccines with other
adjuvants. Because of the antigenic differences, it is less clear
whetherourresultsaddtotheavailabledataonsafetyoffetuses
when using non-adjuvanted seasonal influenza vaccines, for
which limited information on risk of fetal death is available.
3 8
Strengths and limitations of the study
Strengths of this study include its size and its comprehensive
design,withregisterlinkageofindividualleveldata.Information
on H1N1 vaccination was obtained through a nationwide
database, to which reporting was mandatory. This eliminates
recall bias, ensures completeness, and improves the accuracy
of information on timing of vaccination compared with self
reported exposure. Registration of births is mandatory in the
medical birth register; it is therefore unlikely that we missed
any significant number of births. Most cases of spontaneous
abortion in Denmark are likely to be managed by hospital
doctors. According to national guidelines for pregnancy care,
the investigation of early pregnancy bleeds includes
ultrasonographyasacentralpart,andguidelinesfromtheDanish
SocietyofObstetricsandGynecologyindicatethatthediagnosis
of spontaneous abortion requires confirmation by
ultrasonography.
29 30 An ultrasound examination on this
indication could only be carried out by an
obstetrician-gynaecologist. We therefore believe that our
hospitalbasedstrategyforthedetectionofspontaneousabortions
was close to complete. We excluded registered spontaneous
abortionswithlessthansixcompletedweeksofgestation—that
is, early pregnancy loss; only a limited proportion of early
pregnancy losses are recognised clinically, therefore inclusion
of this time period in the analyses would have introduced
outcome misclassification.
A relatively small proportion (13%) of pregnant women in this
nationwide Danish cohort was vaccinated against pandemic
A/H1N1 2009 influenza. This rate is similar to that in some
countriesbutcontrastswiththerateinothers—forexample,the
estimated vaccine coverage among pregnant women was 8% in
Germany,23%inFrance,and40%intheUnitedStates.
31-33The
reason for the low vaccine uptake in Denmark possibly relates
to the fact that the 2009-10 season was the first time that
pregnant women without comorbidities were included among
the target groups for influenza vaccination.
Although we adjusted for many potential confounders, there
might have been differences between vaccinated and
unvaccinatedwomenassociatedwithbothexposureandoutcome
that we could not measure. Of concern would be factors that
could have obscured a risk of fetal death associated with
vaccination.Suchfactorswouldhavetobecommonorstrongly
associatedwithbothvaccinationandreducedriskoffetaldeath.
A few factors might meet these criteria. Although vaccinated
womeninourstudyhadasomewhathigherrateofcomorbidities
compared with unvaccinated women, a large proportion of the
cohort did not have any registered comorbidities. A healthy
vaccinee effect, conferred by, for example, unmeasured factors
suchasdiet,exercise,educationallevel,orsocioeconomicclass,
thatmasksariskoffetaldeathamongvaccinatedwomencannot
be excluded. However, given our observed main estimate of
0.79, the difference in prevalence between the groups would
have to be large and the association with reduced risk of fetal
death strong to obscure a true increased risk associated with
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RESEARCHvaccination. Additionally, we tackled the problem of a healthy
vaccinee effect partly by adjusting for smoking and body mass
index, important risk factors for stillbirth,
34 in a sensitivity
analysis;thisdidnotchangetheestimates.Becausemostpeople
who contract influenza never seek healthcare, the data sources
used in our study did not allow for a precise adjustment for
influenza infection. However, in sensitivity analyses where we
adjusted for influenza infection, defined as the registration of a
hospital diagnosis for influenza or the filling of a prescription
for an anti-influenza antiviral drug, the main results were
unchanged. It should, however, be noted that this definition of
influenza could not detect those cases of influenza infection
wherepatientsdidnotseekhospitalcareorcaseswherepatients
were not prescribed antivirals. In a scenario where a true
increased risk of fetal death associated with vaccination exists,
an increased risk of fetal death conferred by H1N1 infection
itself among unvaccinated women might have biased results
towards the null. However, given the 5% cumulative incidence
of H1N1 infection in Denmark,
35 we reason that confounding
by infection strong enough to contradict the conclusion of this
studyisunlikely.Finally,theabsenceofastronginfluencefrom
unmeasuredconfoundingissupportedbyoursensitivityanalysis,
whichshowedthatwhenadjustingforahypotheticalconfounder
with high prevalence among unvaccinated women and strong
associationwiththeoutcome,theconfounderadjustedestimate
for the association between vaccination and fetal death would
not be far over 1. This sensitivity analysis indicated similar
resultswhenassumingascenariowherevaccinatedwomenhad
a higher prevalence of an unmeasured confounder that was
strongly protective.
Several factors need to be considered when interpreting our
finding of a significantly decreased risk of stillbirth associated
with vaccination against H1N1 influenza. Although H1N1
infection is associated with an increased risk of stillbirth,
36 and
aprotectiveeffectofvaccinationthereforemayseemplausible,
theobjectiveofourstudywastoinvestigateapossibleincreased
risk of adverse events. Additionally, the analysis of stillbirth
was a prespecified secondary outcome and based on a small
number of cases. A chance finding therefore represents a
possibility. Thus the result from this analysis should be viewed
ashypothesisgeneratingandneedsinvestigationinotherstudies
before any conclusions on protective effects are drawn.
Conclusions
In conclusion, this nationwide study is the first to analytically
investigate fetal risks associated with vaccination against
pandemic A/H1N1 2009 influenza in pregnancy. In a cohort of
morethan50000pregnanciestherewasrobustevidenceforthe
safety of the AS03 adjuvanted H1N1 vaccine with respect to
the composite outcome of fetal death and its components,
spontaneous abortion and stillbirth. Additional studies of other
fetaloutcomesareneededtoestablishthecompletesafetyprofile
of this vaccine in pregnancy.
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RESEARCHTables
Table 1| Characteristics of women vaccinated and not vaccinated against pandemic A/H1N1 2009 influenza during pregnancy, nationwide
cohort, Denmark. Values are numbers (percentages) unless stated otherwise
P value* Vaccinated (n=7062) Unvaccinated (n=47 523) Characteristics
Pregnancy outcome:
7006 (99) 43 546 (92) Live birth
8 (0.1) 132 (0.3) Stillbirth
25 (0.4) 1653 (3) Spontaneous abortion
3 (<0.1) 88 (0.2) Ectopic pregnancy
0 (0) 7 (<0.1) Hydatidiform mole
1 (<0.1) 107 (0.2) Other abnormal products of conception
19 (0.3) 1990 (4) Induced abortion
<0.01 30.9 (4.7) 30.0 (5.2) Mean (SD) age at onset of pregnancy
Age group at onset of pregnancy†:
<0.01 90 (1) 1454 (3) <20
691 (10) 6663 (14) 20-24
2199 (31) 15 582 (33) 25-29
2716 (38) 15 916 (33) 30-34
1193 (17) 6759 (14) 35-39
173 (2) 1149 (2) ≥40
County of residence‡:
<0.01 2770 (39) 16 946 (36) Capital region
672 (10) 5956 (13) Sjælland region
1433 (20) 9465 (20) Syddanmark region
1573 (22) 10 722 (23) Midtjylland region
614 (9) 4434 (9) Nordjylland region
Degree of urbanisation§:
293 (4) 2373 (5) ≤49 inhabitants/km
2
<0.01 1690 (24) 12 940 (27) 50-99 inhabitants/km
2
1328 (19) 9907 (21) 100-199 inhabitants/km
2
920 (13) 5147 (11) ≥200 inhabitants/km
2
1415 (20) 8899 (19) Copenhagen suburbs
1416 (20) 8257 (17) Copenhagen
Place of birth¶:
<0.01 6037 (85) 39 609 (83) Denmark
330 (5) 2152 (5) Europe
695 (10) 5762 (12) Other
Month of pregnancy onset, 2009:
<0.01 399 (6) 3447 (7) February
1025 (15) 3771 (8) March
1094 (15) 3832 (8) April
1290 (18) 4031 (8) May
1132 (16) 3854 (8) June
990 (14) 3908 (8) July
714 (10) 4713 (10) August
231 (3) 5896 (12) September
125 (2) 6313 (13) October
61 (1) 6514 (14) November
1 (<0.1) 1244 (3) December
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P value* Vaccinated (n=7062) Unvaccinated (n=47 523) Characteristics
Parity at onset of pregnancy:
<0.01 2851 (40) 22 172 (47) 0
2890 (41) 16 498 (35) 1
1011 (14) 6617 (14) 2
310 (4) 2236 (5) ≥3
<0.01 823 (12) 4752 (10) History of fetal death
Morbidities and drugs**:
<0.01 474 (7) 1736 (4) Pulmonary disease/antiobstructive inhalants
<0.01 279 (4) 1235 (3) Cardiovascular disease/cardiovascular drugs
<0.01 92 (1) 418 (1) Haematological disease
<0.01 195 (3) 703 (1) Diabetes/antidiabetic drugs
<0.01 212 (3) 1031 (2) Neurological disease
0.08 55 (1) 286 (1) Liver and kidney disease
<0.01 57 (1) 222 (0.5) Rheumatic disease
<0.01 93 (1) 418 (1) Inflammatory bowel disease/intestinal anti-inflammatory agents
<0.01 400 (6) 2274 (5) Obesity
<0.01 30 (0.4) 65 (0.1) Immunodeficiency/immunosuppressants
<0.01 920 (13) 5187 (11) Disorders of female pelvic organs/genital tract
0.04 1501 (21) 10 612 (22) Hospital contact for injury or poisoning
<0.01 407 (6) 2323 (5) Antidepressants
0.52 48 (1) 292 (1) Antiepileptics
<0.01 239 (3) 1250 (3) Drugs for peptic ulcer/gastroesophageal reflux
<0.01 1510 (21) 11 066 (23) Contraceptive pills
<0.01 559 (8) 3224 (7) Drugs for in vitro fertilisation
<0.01 96 (1) 475 (1) Thyroid hormones
<0.01 129 (2) 593 (1) Systemic corticosteroids
0.02 652 (9) 3984 (8) Non-steroidal anti-inflammatory drugs
0.02 174 (2) 970 (2) Opioids
<0.01 1799 (25) 10 710 (23) Systemic antibacterial agents
Hospital admissions in past 3 years:
<0.01 3112 (44) 23 350 (49) 0
3301 (47) 20 517 (43) 1-2
479 (7) 2813 (6) 3-4
170 (2) 843 (2) ≥5
Outpatient hospital contacts in past 3 years:
<0.01 2034 (29) 15 648 (33) 0
2648 (37) 18 005 (38) 1-2
1388 (20) 8705 (18) 3-4
992 (14) 5165 (11) ≥5
Drugs used in past 6 months:
<0.01 1971 (28) 15 769 (33) 0
3033 (43) 20 527 (43) 1-2
1267 (18) 7460 (16) 3-4
791 (11) 3767 (8) ≥5
Because of rounding, percentages may not total 100.
*χ
2 test for categorical values and t test for continuous values.
†Missing values: 2 (<0.1%).
‡Missing values: 1504 (2.8%).
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P value* Vaccinated (n=7062) Unvaccinated (n=47 523) Characteristics
§Missing values: 1505 (2.8%).
¶Missing values: 132 (0.2%).
**Comorbidities registered in past three years, and drugs registered in past six months.
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RESEARCHTable 2| Association between vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death in nationwide
cohort of 54 585 pregnancies in Denmark
Hazard ratio (95% CI)
No of events Fetal years at risk No of women Outcome Adjusted* Unadjusted
Fetal death:
1 (reference) 1 (reference) 1785 19 578 47 523 Unvaccinated
0.79 (0.53 to 1.16) 0.82 (0.55 to1.20) 27 1758 7062 Vaccinated
Spontaneous abortion:
1 (reference) 1 (reference) 1649 6835 32 672 Unvaccinated
1.11 (0.71 to 1.73) 1.16 (0.74 to 1.80) 20 211 2736 Vaccinated
Stillbirth:
1 (reference) 1 (reference) 131 12 728 43 663 Unvaccinated
0.44 (0.20 to 0.94) 0.43 (0.20 to 0.92) 7 1547 7014 Vaccinated
*Adjusted for propensity scores.
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RESEARCHTable 3| Sensitivity analyses of association between vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal
death
Adjusted hazard ratio (95% CI)* Adverse pregnancy outcomes
Risk of fetal death according to comorbidity status†:
0.82 (0.44 to 1.53) Comorbidity
0.77 (0.47 to 1.25) No comorbidity
Risk of fetal death according to trimester of vaccination:
0.96 (0.63 to 1.47) First
0.49 (0.26 to 0.93) Second
0.23 (0.03 to 1.61) Third
Main analysis without two week period after vaccination:
0.70 (0.50 to 1.00) Fetal death
0.87 (0.58 to 1.30) Spontaneous abortion
0.45 (0.22 to 0.93) Stillbirth
Main analysis allowing for six week period after vaccination:
0.62 (0.35 to 1.10) Fetal death
1.05 (0.50 to 2.21) Spontaneous abortion
0.40 (0.16 to 0.98) Stillbirth
Body mass index and smoking status included in propensity score:
0.45 (0.21 to 0.96) Stillbirth
Main analysis adjusted for influenza infection‡:
0.78 (0.53 to 1.16) Fetal death
1.11 (0.71 to 1.73) Spontaneous abortion
0.44 (0.20 to 0.94) Stillbirth
*Adjusted for propensity scores.
†Comorbidity if registered with any of the diagnoses listed in table 1, with exception of disorders of female pelvic organ/genital tract and hospital contact for injury
and poisoning.
‡Registered diagnosis of influenza during hospital contact or admission, or filled prescription for anti-influenza antiviral drug.
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RESEARCHFigures
Fig 1 Flow of women through study
Fig 2 Cumulative number of pregnant women in cohort as well as cumulative number of pregnant women vaccinated against
pandemic A/H1N1 2009 influenza throughout study period
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RESEARCHFig 3 Unadjusted Kaplan-Meier curves for primary outcome of fetal death according to vaccination status. Scale on y axis
is restricted to 0.90-1.00
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